View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
September 10, 2020

Coronavirus company news summary – Print Parts delivers 3D-printed NP swabs to support Covid-19 testing – Vivera Pharmaceuticals announces Covid-19 diagnostic solution

By Chloe Kent

Chembio Diagnostics, a point-of-care diagnostic company, has submitted an application for Emergency Use Authorisation (EUA) to the US Food and Drug Administration (FDA) for its new rapid antibody test system, DPP SARS-CoV-2 IgM/IgG. This test system detects antibodies to the Spike Receptor Binding Domain in the blood that the body generates in response to a Covid-19 infection.

Print Parts, a US-based additive manufacturing service, has provided over one million nasopharyngeal (NP) swabs for use in NYC Covid-19 test kits. To manufacture these swabs, Print Parts opened a medical manufacturing lab in Manhattan, in collaboration with NYC Health + Hospitals (H+H), the New York City Economic Development Corporation (NYCEDC), Albert Einstein College of Medicine in the Bronx, and Collab, a Brooklyn-based fabrication lab.

Vivera Pharmaceuticals has announced the launch of a partnership with OmeCare, a CLIA-certified global clinical laboratory provider. The Vivera Pharmaceuticals + OmeCare rapid RT-PCR specimen collection kits provide results on for Covid-19 in less than 48 hours.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network